Evidence map›Paper›PMID 32548935›Full record

ArticleAdvanced healthcare materials2020

Targeted Heating of Mitochondria Greatly Augments Nanoparticle-Mediated Cancer Chemotherapy.

Jiangsheng Xu, James G Shamul, Hai Wang, John Lin, Pranay Agarwal, Mingrui Sun, Xiongbin Lu, Katherine H R Tkaczuk, Xiaoming He

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Recent advances in mitochondrial diseases: From molecular insights to therapeutic perspectives.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2022
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jiangsheng XuFishell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
James G ShamulFishell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Hai WangFishell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
John LinFishell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.
Pranay AgarwalDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Mingrui SunDepartment of Biomedical Engineering, The Ohio State University, Columbus, OH, 43210, USA.
Xiongbin LuDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Katherine H R TkaczukMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA.
Xiaoming HeFishell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA.ORCID 0000-0003-0125-6086
The Ohio State University · USUniversity of Maryland, Baltimore · USUniversity of Maryland, College Park · USIndiana University School of Medicine

Funding

Nanotechnology for targeted therapy and fundamental understanding oftherapeutic resistance in triple negative breast cancerR01CA243023 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING · 2020 to 2024
$2.0M
Nanotechnology enabled targeting of p53 deficiency in human cancerR01CA206366 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI HE, XIAOMING, LU, XIONGBIN · 2016 to 2020
$1.9M
NCI NIH HHS R01 CA206366NCI NIH HHS R01 CA243023
6 · The paper itself

Abstract

Cancer is the second leading cause of mortality globally. Various nanoparticles have been developed to improve the efficacy and safety of chemotherapy, photothermal therapy, and their combination for treating cancer. However, most of the existing nanoparticles are low in both subcellular precision and drug loading content (<≈5%), and the effect of targeted heating of subcellular organelles on the enhancement of chemotherapy has not been well explored. Here, a hybrid Py@Si-TH nanoparticle is reported to first target cancer cells overexpressed with the variant CD44 via its natural ligand HA on the outermost surface of the nanoparticle before cellular uptake, and then target mitochondria after they are taken up inside cells. In addition, the nanoparticle is ultraefficient for encapsulating doxorubicin hydrochloride (DOX) to form Py@Si-TH-DOX nanoparticle. The encapsulation efficiency is ≈100% at the commonly used low feeding ratio of 1:20 (DOX:empty nanoparticle), and >80% at an ultrahigh feeding ratio of 1:1. In combination with near infrared (NIR, 808 nm) laser irradiation, the tumor weight in the Py@Si-TH-DOX treatment group is 8.5 times less than that in the Py@Si-H-DOX (i.e., DOX-laden nanoparticles without mitochondrial targeting) group, suggesting targeted heating of mitochondria is a valuable strategy for enhancing chemotherapy to combat cancer.

Indexed as

NanoparticlesNeoplasmsCell Line, TumorDoxorubicinDrug Delivery SystemsHeatingMitochondriaDoxorubicinconductive polymersdrug deliverymitochondria targetingphotothermal therapyultrahigh anti-cancer efficiency

Identifiers

PMID32548935
PMCPMC7879459
OpenAlexW3034285217

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.